Alzheimer Europe continues to develop and improve its Clinical Trials Watch (CTW), an innovative online resource providing up-to-date accessible information on clinical trials currently recruiting participants in a least one European country. The service provides information on phase II and III clinical trials that are investigating drugs for the prevention and treatment of dementia and/or Alzheimer’s disease (AD). In February 2021, five new trials have been added to the service:
-
ANAVEX®2-73-AD-004 Phase III trial (Anavex Life Sciences Corp)
-
ACI-35.030 Phase II trial (AC Immune)
-
ALZ-801 Phase II trial (Alzheon Inc)
-
Brainshuttle AD Phase II trial (Hoffmann-La Roche)
-
TRAILBLAZER-ALZ 2 Phase II trial (Eli Lilly).
Further information about the CTW is available on: http://www.alzheimer-europe.org/Research/Clinical-Trials-Watch
